Skip to main content
OpenTrials

Clinical trial condition

NSCLC

Explore clinical trials studying NSCLC. Study availability and eligibility vary by location and protocol.

357 public trials 121 recruiting studies
Refine in advanced search Browse all conditions

NSCLC trial results

Recruiting

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

NCT06343402

Conditions
Advanced Lung Carcinoma, Bronchial Neoplasms, Carcinoma, Bronchogenic, +13 more
Locations
  • O'Neal Comprehensive Cancer Center at UAB Birmingham, Alabama, United States
  • University of California - San Diego Moores Cancer Center La Jolla, California, United States
  • University of California San Francisco San Francisco, California, United States
  • UCLA Health - Santa Monica Cancer Care Santa Monica, California, United States
View all 35 locations
View Trial Details
Recruiting

Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer

NCT07563205

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +16 more
Locations
  • CH du Pays d Aix - Service des Maladies Respiratoires Aix-en-Provence, France
  • APHP Hôpital Avicennes Bobigny, France
  • Hôpital Louis Pradel Bron, France
  • Pneumologie Centre François Baclesse Caen, France
View all 16 locations
View Trial Details
Recruiting

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

NCT06620835

Conditions
Lung Diseases, Lung Neoplasms, NSCLC, +5 more
Locations
  • CHU de Brest Brest, France
  • Centre François Baclesse Caen, France
  • CH Métropole-Savoie Chambéry, France
  • Hôpital Louis Pasteur Colmar, France
View all 27 locations
View Trial Details
Recruiting

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

NCT06326411

Conditions
Glioma, MAPK Pathway Gene Mutation, MEK Mutation, +19 more
Locations
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • UCLA Hematology/Oncology Westwood, Los Angeles, California, United States
  • Sarah Cannon Research Institute at Health ONE Denver, Colorado, United States
  • Yale Cancer Center New Haven, Connecticut, United States
View all 23 locations
View Trial Details
Recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

NCT06362369

Conditions
ALK Genomic Tumor Aberrations, Adenocarcinoma, Adenoma, +69 more
Locations
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Florida Cancer Specialists Lake Mary, Florida, United States
  • Dartmouth Hitchcock Lebanon, New Hampshire, United States
  • Brown University Health Cancer Institute Providence, Rhode Island, United States
View Trial Details
Recruiting

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

NCT05987644

Conditions
Brain Diseases, Brain Metastases, Brain Neoplasms, +13 more
Locations
  • Stanford University Stanford, California, United States
  • University of Colorado Cancer Center Aurora, Colorado, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details

Related conditions